Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial.

van Vollenhoven RF, Keystone EC, Strand V, Pacheco-Tena C, Vencovský J, Behrens F, Racewicz A, Zipp D, Rharbaoui F, Wolter R, Knierim L, Schmeidl R, Zhou X, Aigner S, Dälken B, Wartenberg-Demand A; TREAT2b study team.

Ann Rheum Dis. 2018 Apr;77(4):495-499. doi: 10.1136/annrheumdis-2017-212478. Epub 2018 Jan 17.

PMID:
29343509
2.

The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.

Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Pollock C, Wheeler DC, Xie J, Zhang H, Zinman B, Desai M, Perkovic V; CREDENCE study investigators.

Am J Nephrol. 2017 Dec 13;46(6):462-472. doi: 10.1159/000484633. [Epub ahead of print]

3.

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators.

N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.

4.

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.

Sandborn WJ, Feagan BG, Wolf DC, D'Haens G, Vermeire S, Hanauer SB, Ghosh S, Smith H, Cravets M, Frohna PA, Aranda R, Gujrathi S, Olson A; TOUCHSTONE Study Group.

N Engl J Med. 2016 May 5;374(18):1754-62. doi: 10.1056/NEJMoa1513248.

5.

Validation of spectrophotometric methods of assaying metronidazole in capsules.

Myhal A, Dobrova A, Golovchenko O, Georgiyants V.

Ceska Slov Farm. 2015 Nov;64(5):225-7. No abstract available.

PMID:
28649825
6.

European evidence based consensus for endoscopy in inflammatory bowel disease.

Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, Ferrante M, Götz M, Katsanos KH, Kießlich R, Ordás I, Repici A, Rosa B, Sebastian S, Kucharzik T, Eliakim R; European Crohn's and Colitis Organisation.

J Crohns Colitis. 2013 Dec;7(12):982-1018. doi: 10.1016/j.crohns.2013.09.016. Epub 2013 Nov 1. No abstract available.

7.

Vedolizumab as induction and maintenance therapy for Crohn's disease.

Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A; GEMINI 2 Study Group.

N Engl J Med. 2013 Aug 22;369(8):711-21. doi: 10.1056/NEJMoa1215739.

8.

[Soviet reference sera and their use in the control of the quality of biochemical studies].

Garanina EN, Golovchenko OM.

Lab Delo. 1988;(6):71-3. Russian. No abstract available.

PMID:
2459491
9.

[Changes in SH groups as an indicator of the denaturation of control sera].

Golovchenko OM, Ugrimov SA, Smyshliaeva VI.

Lab Delo. 1986;(8):468-70. Russian. No abstract available.

PMID:
2429049
10.

[Component stability of a reference horse serum].

Golovchenko OM.

Lab Delo. 1982;(1):62-3. Russian. No abstract available.

PMID:
6174801
11.

[Standard solution for determining blood serum triglycerides].

Symshliaeva VI, Golovchenko OM.

Lab Delo. 1981;(11):659-61. Russian. No abstract available.

PMID:
6170816
12.

[Modification of a unified method of determination of total blood serum phospholipids].

Smyshliaeva VI, Golovchenko OM.

Lab Delo. 1980;(5):293-4. Russian. No abstract available.

PMID:
6156284

Supplemental Content

Loading ...
Support Center